New research indicates that pegylated interferon-alpha (PEG-IFN-α) is an effective and manageable treatment option for patients with various blood-related neoplasms, including systemic mastocytosis (SM).
Interferon-alpha is an immunotherapy used to enhance the immune system’s response against various viral infections and cancers; while it is currently FDA-approved for conditions like chronic hepatitis and certain leukemias, its use in SM remains largely off-label.
A real-world retrospective study, published in Acta Medica, found that patients with SM who received PEG-IFN-α as first-line therapy showed clinical improvement.
The cohort included a total of 30 patients with various blood disorders, including three individuals diagnosed with SM. Beyond its use as a first-line treatment, the research showed that PEG-IFN-α was often used when other therapies weren’t effective or created severe side effects.
Read more about SM therapies
However, harmful side effects led six patients (20%) to discontinue therapy. These included cytopenias (low blood cell counts), influenza-like symptoms and elevated liver enzymes. Notably, these side effects are comparable to those reported with conventional interferon-alpha treatment, suggesting that the pegylated version maintains a similar safety profile while offering improved pharmacological benefits.
PEG-IFN-α is a modified version of conventional interferon-alpha that has been chemically bonded to a molecule of polyethylene glycol (PEG). This process, known as pegylation, significantly improves the drug’s pharmacokinetics by allowing it to remain in the body longer and at more stable concentrations. For patients, this translates to a much more convenient dosing schedule, typically requiring only one injection per week instead of the three injections required with standard interferon.
These findings complement recent reports on a 2026 preliminary study, which suggested that PEG-IFN-α may offer a promising disease-modifying approach to prevent bone damage in nonadvanced SM.
Despite these encouraging real-world outcomes, the authors noted that the lack of formal approval for the medication in SM coupled with limited availability in some areas often prevents patients from accessing this treatment.
Sign up here to get the latest news, perspectives, and information about SM sent directly to your inbox. Registration is free and only takes a minute.
